Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 25,738 shares at $39.95 ($1.0M) on 2017-08-29, disclosed to the SEC on 2017-08-31.
Open-market sale of $1.0M JUNO by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.95 | 12,869 | $514K | 50.0% |
| 2 | $39.95 | 12,869 | $514K | 50.0% |
| Total | $39.95 avg | 25,738 | $1.0M | 100% |
| Filing → |
| JUNO | SELL | 2018-02-14 | $356K | — | Filing → |
| JUNO | SELL | 2018-02-09 | $600K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |